> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest FDA Warning Letters
- URL: https://www.fdaweb.com/latest-fda-warning-letters-45/
- Published: 2020-11-17T12:00:00.000Z
- Updated: 2026-09-14T16:36:38.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5148108

FDA has posted its latest batch of Warning Letters. They can be accessed by clicking on the link following each letter.

**Family Pharmacy**, Statesville, NC (11/6): FDA inspected the firm 2/3-2/12 and cited multiple drug compounding and GMP violations. For example, it failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions. It also failed to adequately design the facility with adequate separation or defined areas or such other control systems necessary to prevent contamination or mix-ups. To view the Warning Letter, click [here](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/family-pharmacy-statesville-inc-611664-11062020?ref=fdaweb.com).

**Quten Research Institute**, Pine Brook, NJ (11/5): FDA recently reviewed the firm’s Web site and determined that it takes orders for Qunol Ultra CoQ10 and Qunol Extra Strength Turmeric. The claims on the Web site make the products unapproved new drugs. For example, one claim said: “Researchers theorize that some people that suffer from high blood pressure also exhibit CoQ10 deficiency. Multiple studies have reported that CoQ10 had a blood pressure lowering (hypotensive) effect and that this might be caused in part by correcting this deficiency.” The letter told the company to take prompt action to correct the cited violations. To view the letter, click [here](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/quten-research-institute-llc-610021-11052020?ref=fdaweb.com).